QuellTX Logo
04/08/21

Quell Therapeutics to Present at the 2021 Wedbush Pacgrow Healthcare Virtual Conference

London, UK and Boston, MA, USA, August 4, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that Iain McGill, Chief Executive Officer of Quell Therapeutics, will participate in a panel discussion, Out of Body Experience – Transplant: Two Genotypes Living in Harmony, at the Wedbush Pacgrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 7:55 p.m. BST (2:55 p.m. ET).

About Quell Therapeutics

Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.

The Company is leveraging its pioneering phenotype lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches.

Quell’s lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases. www.quell-tx.com.

Contacts

Media: Mark Swallow, Frazer Hall, Eleanor Perkins
MEDiSTRAVA Consulting
+44 207 638 9571
Quell-Tx@Medistrava.com

Investors: Christina Tartaglia
Stern Investor Relations, Inc.
+1 212 362 1200
christina@sternir.com

10/07/24

Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors

London, UK – July 10, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Luke Beshar as Independent Chair of…...

Read More
05/06/24

Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR- Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients

Progress in the LIBERATE trial was presented at the American Transplant Congress today London, UK – June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the…...

Read More
02/05/24

Quell Therapeutics Highlights Clinical Potential of QEL-001 and its Multi-Modular Treg Cell Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Data demonstrating Quell’s ability to engineer Tregs to enhance their specific targeting and durability while maintaining their suppressive function and phenotypic stability to be presented in Oral and Poster sessions London, UK – May 2, 2024 – Quell Therapeutics Ltd (“Quell”),…...

Read More